Recent results from the DARE-ESKD Phase 1 trial (NCT05343078), on Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients including a total of 7 patients (2 on peritoneal dialysis) have shown that dapagliflozin was well tolerated, slightly dialyzable, and had non-accumulating pharmacokinetic properties35 (Table 2)
Given that multiple therapeutic options are available for CHE, treatment strategies should be individualized by considering not only efficacy and adverse effects but also the patients disease severity, lifestyle, preferences, and economic burden
Healing Peptides: 8-12 Weeks BPC-157 & TB-500 : A standard cycle is 8-12 weeks
Glycemic indices of five varieties of dates in healthy and diabetic subjects
Disruption of the balance between these two factors is a determining factor in the onset of ferroptosis
GLP-1 medications are powerful tools for managing type 2 diabetes and supporting weight loss, but nutrition is what keeps the process sustainable